[1] |
GIL-VERNET S, AMADO A, ORTEGA F, et al. Gastrointestinal complications in renal transplant recipients: MITOS study[J]. Transplant Proc, 2007, 39(7): 2190-2193. DOI: 10.1016/j.transproceed.2007.07.015.
|
[2] |
GIBSON CM, CHILDS-KEAN LM, NAZIRUDDIN Z, et al. The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation[J]. Transpl Infect Dis, 2021, 23(1): e13397. DOI: 10.1111/tid.13397.
|
[3] |
GABARRE P, LOENS C, TAMZALI Y, et al. Immunosuppressive therapy after solid organ transplantation and the gut microbiota: bidirectional interactions with clinical consequences[J]. Am J Transplant, 2022, 22(4): 1014-1030. DOI: 10.1111/ajt.16836.
|
[4] |
ANGARONE M, ISON MG. Diarrhea in solid organ transplant recipients[J]. Curr Opin Infect Dis, 2015, 28(4): 308-316. DOI: 10.1097/QCO.0000000000000172.
|
[5] |
EKBERG H, KYLLÖNEN L, MADSEN S, et al. Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: a multinational survey of nephrologists[J]. Transplantation, 2007, 84(8): 1052-1054. DOI: 10.1097/01.tp.0000284983.89207.1a.
|
[6] |
ALTIPARMAK MR, TRABLUS S, PAMUK ON, et al. Diarrhoea following renal transplantation[J]. Clin Transplant, 2002, 16(3): 212-216. DOI: 10.1034/j.1399-0012.2002.01129.x.
|
[7] |
ECHENIQUE IA, PENUGONDA S, STOSOR V, et al. Diagnostic yields in solid organ transplant recipients admitted with diarrhea[J]. Clin Infect Dis, 2015, 60(5): 729-737. DOI: 10.1093/cid/ciu880.
|
[8] |
SINGH M, HEINCELMAN M. Disseminated nontuberculous mycobacterium presenting as chronic diarrhea and wasting[J]. J Investig Med High Impact Case Rep, 2022, 10: 23247096221101860. DOI: 10.1177/23247096221101860.
|
[9] |
WANG HY, YEH MK, TIAN YF, et al. Effect of prolonged diarrhea in renal transplant recipients at a single center in Taiwan[J]. Transplant Proc, 2016, 48(3): 870-873. DOI: 10.1016/j.transproceed.2015.12.075.
|
[10] |
TANAKA R, MATSUMOTO A, TATSUTA R, et al. Sustained suppression of enterohepatic circulation of mycophenolic acid by antimicrobial-associated diarrhea in a kidney transplant recipient with Crohn's disease: a case report[J]. Clin Case Rep, 2022, 10(6): e05914. DOI: 10.1002/ccr3.5914.
|
[11] |
BELGA S. Chronic diarrhea secondary to norovirus infection in kidney transplant recipients: early recognition is key[J]. Transplantation, 2021, 105(12): 2524-2525. DOI: 10.1097/TP.0000000000003709.
|
[12] |
VYAS VD, PARAMESWARAN SA, PARAMASIVAN P, et al. Etiological profile of diarrhea in solid organ transplant recipients at a tertiary care center in Southern India[J]. Transpl Infect Dis, 2021, 23(4): e13584. DOI: 10.1111/tid.13584.
|
[13] |
SEKMEK S, YILDIRIM T, KOC NS, et al. Efficacy and safety of switching to azathioprine for mycophenolate-induced diarrhea in renal transplant recipients[J]. Transplant Proc, 2021, 53(6): 1951-1956. DOI: 10.1016/j.transproceed.2021.06.020.
|
[14] |
JARDOU M, PROVOST Q, BROSSIER C, et al. Alteration of the gut microbiome in mycophenolate-induced enteropathy: impacts on the profile of short-chain fatty acids in a mouse model[J]. BMC Pharmacol Toxicol, 2021, 22(1): 66. DOI: 10.1186/s40360-021-00536-4.
|
[15] |
CALMET FH, YARUR AJ, PUKAZHENDHI G, et al. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation[J]. Ann Gastroenterol, 2015, 28(3): 366-373.
|
[16] |
BHATTACHARYA S, STOLERU G, PATEL P, et al. Characterization of mycophenolate mofetil gastrointestinal toxicity and risk factors for severe disease and poor prognosis[J]. Inflamm Bowel Dis, 2022, 28(5): 811-814. DOI: 10.1093/ibd/izab254.
|
[17] |
HISSONG E, MOSTYKA M, YANTISS RK. Histologic features of tacrolimus-induced colonic injury[J]. Am J Surg Pathol, 2022, 46(1): 118-123. DOI: 10.1097/PAS.0000000000001761.
|
[18] |
ALKHATIB AA. Sirolimus-induced intractable chronic diarrhea: a case report[J]. Transplant Proc, 2006, 38(5): 1298-1300. DOI: 10.1016/j.transproceed.2006.02.123.
|
[19] |
ARSLAN H, INCI EK, AZAP OK, et al. Etiologic agents of diarrhea in solid organ recipients[J]. Transpl Infect Dis, 2007, 9(4): 270-275. DOI: 10.1111/j.1399-3062.2007.00237.x.
|
[20] |
AULAGNON F, SCEMLA A, DEWOLF S, et al. Diarrhea after kidney transplantation: a new look at a frequent symptom[J]. Transplantation, 2014, 98(8): 806-816. DOI: 10.1097/TP.0000000000000335.
|
[21] |
ORTIZ-BALBUENA J, ROYUELA A, CALDERÓN-PARRA J, et al. Risk factors for clostridioides difficile diarrhea in solid organ transplantation recipients[J]. Transplant Proc, 2021, 53(10): 2826-2832. DOI: 10.1016/j.transproceed.2021.09.047.
|
[22] |
HOSSEINI-MOGHADDAM SM, LUO B, BOTA SE, et al. Incidence and outcomes associated with clostridioides difficile infection in solid organ transplant recipients[J]. JAMA Netw Open, 2021, 4(12): e2141089. DOI: 10.1001/jamanetworkopen.2021.41089.
|
[23] |
ROOS-WEIL D, AMBERT-BALAY K, LANTERNIER F, et al. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea[J]. Transplantation, 2011, 92(1): 61-69. DOI: 10.1097/TP.0b013e31821c9392.
|
[24] |
SCHORN R, HÖHNE M, MEERBACH A, et al. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution[J]. Clin Infect Dis, 2010, 51(3): 307-314. DOI: 10.1086/653939.
|
[25] |
JORGENSON MR, DESCOUROUEZ JL, KLEIBOEKER H, et al. Cytomegalovirus antiviral stewardship in solid organ transplant recipients: a new gold standard[J]. Transpl Infect Dis, 2022, 24(5): e13864. DOI: 10.1111/tid.13864.
|
[26] |
KOTTON CN, TORRE-CISNEROS J, International CMV Symposium Faculty, et al. Cytomegalovirus in the transplant setting: where are we now and what happens next? a report from the International CMV Symposium 2021[J]. Transpl Infect Dis, 2022, 24(6): e13977. DOI: 10.1111/tid.13977.
|
[27] |
HOGAN JI, STEINER KL, SIFRI CD. First report of sexually transmitted primary cytomegalovirus proctocolitis in a renal transplant recipient[J]. Transpl Infect Dis, 2022, 24(1): e13680. DOI: 10.1111/tid.13680.
|
[28] |
FERGUSON J, MOONEY K, SALEEM A, et al. Cutaneous cytomegalovirus - a case of disseminated cytomegalovirus presenting with extensive ulcerative skin lesions in a renal transplant recipient[J]. Transpl Infect Dis, 2021, 23(4): e13582. DOI: 10.1111/tid.13582.
|
[29] |
YANG QH, MA XP, DAI DL, et al. Gastrointestinal cytomegalovirus disease secondary to measles in an immunocompetent infant: a case report[J]. World J Gastroenterol, 2021, 27(15): 1655-1663. DOI: 10.3748/wjg.v27.i15.1655.
|
[30] |
ABBAS A, ZIMMER AJ, FLORESCU D. Viral enteritis in solid-organ transplantation[J]. Viruses, 2021, 13(10): 2019. DOI: 10.3390/v13102019.
|
[31] |
ARREGUI GARCIA I, ELÍA LÒPEZ M, AGUINAGA PÉREZ A, et al. Cryptosporidiosis in immunosuppressed renal transplant patient[J]. Rev Esp Quimioter, 2021, 34(2): 164-166. DOI: 10.37201/req/136.2020.
|
[32] |
SENEGHINI M, PETERMICHL V, FREI R, et al. Microsporidiosis in a solid organ transplant recipient[J]. Int J Infect Dis, 2021, 108: 18-19. DOI: 10.1016/j.ijid.2021.04.084.
|
[33] |
GIOCO R, CORONA D, EKSER B, et al. Gastrointestinal complications after kidney transplantation[J]. World J Gastroenterol, 2020, 26(38): 5797-5811. DOI: 10.3748/wjg.v26.i38.5797.
|
[34] |
SEN A, CALLISEN H, LIBRICZ S, et al. Complications of solid organ transplantation: cardiovascular, neurologic, renal, and gastrointestinal[J]. Crit Care Clin, 2019, 35(1): 169-186. DOI: 10.1016/j.ccc.2018.08.011.
|
[35] |
AXELRAD JE, CADWELL KH, COLOMBEL JF, et al. The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review[J]. Therap Adv Gastroenterol, 2021, 14: 17562848211004493. DOI: 10.1177/17562848211004493.
|
[36] |
SAMPAIO MS, CHO YW, QAZI Y, et al. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database[J]. Transplantation, 2012, 94(10): 990-998. DOI: 10.1097/TP.0b013e318270bc7b.
|
[37] |
SPRANGERS B, RIELLA LV, DIERICKX D. Posttransplant lymphoproliferative disorder following kidney transplantation: a review[J]. Am J Kidney Dis, 2021, 78(2): 272-281. DOI: 10.1053/j.ajkd.2021.01.015.
|
[38] |
KATZ-GREENBERG G, GHIMIRE S, ZHAN T, et al. Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature[J]. Am J Cancer Res, 2021, 11(9): 4624-4637.
|
[39] |
MAES B, HADAYA K, DE MOOR B, et al. Severe diarrhea in renal transplant patients: results of the DIDACT study[J]. Am J Transplant, 2006, 6(6): 1466-1472. DOI: 10.1111/j.1600-6143.2006.01320.x.
|
[40] |
BUNNAPRADIST S, LENTINE KL, BURROUGHS TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure[J]. Transplantation, 2006, 82(1): 102-107. DOI: 10.1097/01.tp.0000225760.09969.1f.
|
[41] |
MULLANE KM, DUBBERKE ER, AST ID Community of Practice. Management of clostridioides (formerly clostridium) difficile infection (CDI) in solid organ transplant recipients: guidelines from the American Society of Transplantation Community of Practice[J]. Clin Transplant, 2019, 33(9): e13564. DOI: 10.1111/ctr.13564.
|
[42] |
MAHATANAN R, TANTISATTAMO E, CHAROENPONG P, et al. Outcomes of C difficile infection in solid-organ transplant recipients: the National Inpatient Sample (NIS) 2015-2016[J]. Transpl Infect Dis, 2021, 23(1): e13459. DOI: 10.1111/tid.13459.
|
[43] |
DUDZICZ-GOJOWY S, WIĘCEK A, ADAMCZAK M. Clostridioides difficile infection in patients after organ transplantation-a narrative overview[J]. J Clin Med, 2022, 11(15): 4365. DOI: 10.3390/jcm11154365.
|
[44] |
REIGADAS E, VAN PREHN J, FALCONE M, et al. How to: prophylactic interventions for prevention of clostridioides difficile infection[J]. Clin Microbiol Infect, 2021, 27(12): 1777-1783. Doi: 10.1016/j.cmi.2021.06.037.
|
[45] |
MCDONALD LC, GERDING DN, JOHNSON S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) [J]. Clin Infect Dis, 2018, 66(7): 987-994. DOI: 10.1093/cid/ciy149.
|
[46] |
KHORUTS A, STALEY C, SADOWSKY MJ. Faecal microbiota transplantation for clostridioides difficile: mechanisms and pharmacology[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 67-80. DOI: 10.1038/s41575-020-0350-4.
|
[47] |
CHENG YW, PHELPS E, GANAPINI V, et al. Fecal microbiota transplantation for the treatment of recurrent and severe clostridium difficile infection in solid organ transplant recipients: a multicenter experience[J]. Am J Transplant, 2019, 19(2): 501-511. DOI: 10.1111/ajt.15058.
|
[48] |
DURAND CM, MARR KA, ARNOLD CA, et al. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients[J]. Clin Infect Dis, 2013, 57(11): 1550-1559. DOI: 10.1093/cid/cit521.
|
[49] |
RUENROENGBUN N, NUMTHAVAJ P, SAPANKAEW T, et al. Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis[J]. Transpl Int, 2021, 34(12): 2720-2734. DOI: 10.1111/tri.14122.
|
[50] |
RAZONABLE RR. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients[J]. Infect Dis Clin North Am, 2013, 27(2): 317-342. DOI: 10.1016/j.idc.2013.02.005.
|
[51] |
RAZONABLE RR, HUMAR A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13512. DOI: 10.1111/ctr.13512.
|
[52] |
HELLEMANS R, ABRAMOWICZ D. Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention[J]. Nephrol Dial Transplant, 2022, 37(5): 810-816. DOI: 10.1093/ndt/gfaa249.
|
[53] |
HAKKI M. Moving past ganciclovir and foscarnet: advances in CMV therapy[J]. Curr Hematol Malig Rep, 2020, 15(2): 90-102. DOI: 10.1007/s11899-020-00557-6.
|
[54] |
OKI R, HIDAKA S, SASAKI A, et al. De novo ulcerative colitis after kidney transplantation treated with infliximab[J]. CEN Case Rep, 2021, 10(4): 500-505. DOI: 10.1007/s13730-021-00599-6.
|
[55] |
PEVERELLE M, ASADI K, DE CRUZ P. Ustekinumab is a safe and effective biological agent for Crohn's disease in a liver transplant patient[J]. J Crohns Colitis, 2020, 14(10): 1498-1499. DOI: 10.1093/ecco-jcc/jjaa062.
|
[56] |
INDRIOLO A, RAVELLI P. Clinical management of inflammatory bowel disease in the organ recipient[J]. World J Gastroenterol, 2014, 20(13): 3525-3533. DOI: 10.3748/wjg.v20.i13.3525.
|